Bone Grafts and Substitutes - Medical Devices Pipeline Assessment, 2020

GlobalData's Medical Devices sector report, "Bone Grafts and Substitutes - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Bone Grafts and Substitutes pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Bone Grafts and Substitutes are used in surgical procedures of bones in the human body under two cases either when there is a breakage in the bone or in the case of a void between or in the bones due to number of factors such as age and degenerative diseases.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the Bone Grafts and Substitutes under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Bone Grafts and Substitutes and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Bone Grafts and Substitutes under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Bone Grafts and Substitutes Overview

3 Products under Development

• 3.1 Bone Grafts and Substitutes - Pipeline Products by Stage of Development
• 3.2 Bone Grafts and Substitutes - Pipeline Products by Segment
• 3.3 Bone Grafts and Substitutes - Pipeline Products by Territory
• 3.4 Bone Grafts and Substitutes - Pipeline Products by Regulatory Path
• 3.5 Bone Grafts and Substitutes - Pipeline Products by Estimated Approval Date
• 3.6 Bone Grafts and Substitutes - Ongoing Clinical Trials

4 Bone Grafts and Substitutes - Pipeline Products under Development by Companies

• 4.1 Bone Grafts and Substitutes Companies - Pipeline Products by Stage of Development
• 4.2 Bone Grafts and Substitutes - Pipeline Products by Stage of Development

5 Bone Grafts and Substitutes Companies and Product Overview

• 5.1 Adocia SAS Company Overview
  • 5.1.1 Adocia SAS Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 Aesculap Biologics LLC Company Overview
  • 5.2.1 Aesculap Biologics LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.3 Agenta Biotechnologies Inc (Inactive) Company Overview
  • 5.3.1 Agenta Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.4 Amend Surgical, Inc. Company Overview
  • 5.4.1 Amend Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.5 Anika Therapeutics Inc Company Overview
  • 5.5.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.6 Antibe Therapeutics Inc Company Overview
  • 5.6.1 Antibe Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.7 Aperion Biologics Corp Company Overview
  • 5.7.1 Aperion Biologics Corp Pipeline Products & Ongoing Clinical Trials Overview
• 5.8 Arthro Kinetics AG Company Overview
  • 5.8.1 Arthro Kinetics AG Pipeline Products & Ongoing Clinical Trials Overview
• 5.9 Aursos, Inc (Inactive) Company Overview
  • 5.9.1 Aursos, Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.10 Baxter International Inc Company Overview
  • 5.10.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.11 Berkeley Advanced Biomaterials Inc Company Overview
  • 5.11.1 Berkeley Advanced Biomaterials Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.12 Bio2 Technologies Inc Company Overview
  • 5.12.1 Bio2 Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.13 Bioactive Bone Substitutes Plc Company Overview
  • 5.13.1 Bioactive Bone Substitutes Plc Pipeline Products & Ongoing Clinical Trials Overview
• 5.14 BioGend Therapeutics Co Ltd Company Overview
  • 5.14.1 BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.15 BiolMed Innovations Pvt Ltd Company Overview
  • 5.15.1 BiolMed Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.16 Biomatlante SA Company Overview
  • 5.16.1 Biomatlante SA Pipeline Products & Ongoing Clinical Trials Overview
• 5.17 Bioregeneration Technologies, Inc Company Overview
  • 5.17.1 Bioregeneration Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.18 Biorez Inc Company Overview
  • 5.18.1 Biorez Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.19 Bio-Scaffold International Pte Ltd Company Overview
  • 5.19.1 Bio-Scaffold International Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.20 Bioventus LLC Company Overview
  • 5.20.1 Bioventus LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.21 Bone Biologics Corp Company Overview
  • 5.21.1 Bone Biologics Corp Pipeline Products & Ongoing Clinical Trials Overview
• 5.22 Bone Solutions Inc Company Overview
  • 5.22.1 Bone Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.23 BoneGrafix, Inc. Company Overview
  • 5.23.1 BoneGrafix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.24 BoneSupport AB Company Overview
  • 5.24.1 BoneSupport AB Pipeline Products & Ongoing Clinical Trials Overview
• 5.25 Bonus BioGroup Ltd Company Overview
  • 5.25.1 Bonus BioGroup Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.26 Calcitec, Inc. Company Overview
  • 5.26.1 Calcitec, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.27 Carmell Therapeutics Corp Company Overview
  • 5.27.1 Carmell Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview
• 5.28 Case Western Reserve University Company Overview
  • 5.28.1 Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview
• 5.29 CeraPedics Inc Company Overview
  • 5.29.1 CeraPedics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.30 Citrics Biomedical, LLC (Inactive) Company Overview
  • 5.30.1 Citrics Biomedical, LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.31 Collagen Solutions Plc Company Overview
  • 5.31.1 Collagen Solutions Plc Pipeline Products & Ongoing Clinical Trials Overview
• 5.32 Collplant Biotechnologies Ltd Company Overview
  • 5.32.1 Collplant Biotechnologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.33 Daewoong Pharmaceutical Co Ltd Company Overview
  • 5.33.1 Daewoong Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.34 Dimension Inx LLC Company Overview
  • 5.34.1 Dimension Inx LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.35 Drexel University Company Overview
  • 5.35.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview
• 5.36 DSM Biomedical BV Company Overview
  • 5.36.1 DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview
• 5.37 Element Orthopedics Inc (Inactive) Company Overview
  • 5.37.1 Element Orthopedics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.38 ElutInc Company Overview
  • 5.38.1 ElutInc Pipeline Products & Ongoing Clinical Trials Overview
• 5.39 Ember Therapeutics Inc Company Overview
  • 5.39.1 Ember Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.40 EpiBone Inc Company Overview
  • 5.40.1 EpiBone Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.41 Eskisehir Osmangazi University Company Overview
  • 5.41.1 Eskisehir Osmangazi University Pipeline Products & Ongoing Clinical Trials Overview
• 5.42 EternoGen Aesthetics LLC Company Overview
  • 5.42.1 EternoGen Aesthetics LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.43 Exactech Inc Company Overview
  • 5.43.1 Exactech Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.44 Ferring Pharmaceuticals AS Company Overview
  • 5.44.1 Ferring Pharmaceuticals AS Pipeline Products & Ongoing Clinical Trials Overview
• 5.45 Gene Biotherapeutics Inc Company Overview
  • 5.45.1 Gene Biotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.46 Graftoss Limited Company Overview
  • 5.46.1 Graftoss Limited Pipeline Products & Ongoing Clinical Trials Overview
• 5.47 Graftys SA Company Overview
  • 5.47.1 Graftys SA Pipeline Products & Ongoing Clinical Trials Overview
• 5.48 Hospital for Special Surgery Company Overview
  • 5.48.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview
• 5.49 Induce Biologics Inc. Company Overview
  • 5.49.1 Induce Biologics Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.50 Innovoss Inc. (Inactive) Company Overview
  • 5.50.1 Innovoss Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.51 IRCCS San Raffaele Hospital Company Overview
  • 5.51.1 IRCCS San Raffaele Hospital Pipeline Products & Ongoing Clinical Trials Overview
• 5.52 Isto Biologics Company Overview
  • 5.52.1 Isto Biologics Pipeline Products & Ongoing Clinical Trials Overview
• 5.53 Johns Hopkins University Company Overview
  • 5.53.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
• 5.54 kasios sas Company Overview
  • 5.54.1 kasios sas Pipeline Products & Ongoing Clinical Trials Overview
• 5.55 King's College London Company Overview
  • 5.55.1 King's College London Pipeline Products & Ongoing Clinical Trials Overview
• 5.56 Kuros Biosciences AG Company Overview
  • 5.56.1 Kuros Biosciences AG Pipeline Products & Ongoing Clinical Trials Overview
• 5.57 Kytogenics Pharmaceuticals Inc Company Overview
  • 5.57.1 Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.58 Lattice Biologics Ltd Company Overview
  • 5.58.1 Lattice Biologics Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.59 Locate Bio Ltd Company Overview
  • 5.59.1 Locate Bio Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.60 Maxigen Biotech Inc Company Overview
  • 5.60.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.61 Medisse BV (Inactive) Company Overview
  • 5.61.1 Medisse BV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.62 Medtronic Plc Company Overview
  • 5.62.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
• 5.63 Miromatrix Medical Inc Company Overview
  • 5.63.1 Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.64 N2 Biomedical Company Overview
  • 5.64.1 N2 Biomedical Pipeline Products & Ongoing Clinical Trials Overview
• 5.65 National Center of Innovation for Biomaterials in Orthopaedic Research Company Overview
  • 5.65.1 National Center of Innovation for Biomaterials in Orthopaedic Research Pipeline Products & Ongoing Clinical Trials Overview
• 5.66 National University of Science and Technology MiSiS Company Overview
  • 5.66.1 National University of Science and Technology MiSiS Pipeline Products & Ongoing Clinical Trials Overview
• 5.67 Nutech Medical Inc Company Overview
  • 5.67.1 Nutech Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.68 NuVasive Inc Company Overview
  • 5.68.1 NuVasive Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.69 Oligo Medic Inc Company Overview
  • 5.69.1 Oligo Medic Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.70 Orthocell Ltd Company Overview
  • 5.70.1 Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.71 OrthoMedex LLC Company Overview
  • 5.71.1 OrthoMedex LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.72 Orthosera GmbH Company Overview
  • 5.72.1 Orthosera GmbH Pipeline Products & Ongoing Clinical Trials Overview
• 5.73 OssiFi, Inc. Company Overview
  • 5.73.1 OssiFi, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.74 OsteoNovus, LLC Company Overview
  • 5.74.1 OsteoNovus, LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.75 Osteopore International Pte Ltd Company Overview
  • 5.75.1 Osteopore International Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.76 Particle3D Company Overview
  • 5.76.1 Particle3D Pipeline Products & Ongoing Clinical Trials Overview
• 5.77 PolyPid Ltd Company Overview
  • 5.77.1 PolyPid Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.78 Polytechnic University of Catalonia Company Overview
  • 5.78.1 Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview
• 5.79 Promimic AB Company Overview
  • 5.79.1 Promimic AB Pipeline Products & Ongoing Clinical Trials Overview
• 5.80 ReCaPP Company Overview
  • 5.80.1 ReCaPP Pipeline Products & Ongoing Clinical Trials Overview
• 5.81 RepRegen Ltd. (Inactive) Company Overview
  • 5.81.1 RepRegen Ltd. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.82 Revivicor Inc Company Overview
  • 5.82.1 Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.83 RTI Surgical Inc Company Overview
  • 5.83.1 RTI Surgical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.84 Sanara MedTech Inc Company Overview
  • 5.84.1 Sanara MedTech Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.85 Scil Technology GmbH Company Overview
  • 5.85.1 Scil Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview
• 5.86 SDIP Innovations Pty Ltd Company Overview
  • 5.86.1 SDIP Innovations Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.87 SIRAKOSS Ltd Company Overview
  • 5.87.1 SIRAKOSS Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.88 Sofregen Medical Inc Company Overview
  • 5.88.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.89 Soteira Inc Company Overview
  • 5.89.1 Soteira Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.90 SurgaColl Technologies Ltd Company Overview
  • 5.90.1 SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.91 SurGenTec LLC Company Overview
  • 5.91.1 SurGenTec LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.92 T&R Biofab Co Ltd Company Overview
  • 5.92.1 T&R Biofab Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.93 TBF Genie Tissulaire Company Overview
  • 5.93.1 TBF Genie Tissulaire Pipeline Products & Ongoing Clinical Trials Overview
• 5.94 The Chinese University of Hong Kong Company Overview
  • 5.94.1 The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview
• 5.95 TheraCell, Inc. Company Overview
  • 5.95.1 TheraCell, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.96 Theragnostic Technologies Inc Company Overview
  • 5.96.1 Theragnostic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.97 Tissue Regeneration Systems, Inc. Company Overview
  • 5.97.1 Tissue Regeneration Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.98 Trinity College Dublin Company Overview
  • 5.98.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview
• 5.99 University of California San Diego Company Overview
  • 5.99.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
• 5.100 University of Edinburgh Company Overview
  • 5.100.1 University of Edinburgh Pipeline Products & Ongoing Clinical Trials Overview
• 5.101 University of Malaya Company Overview
  • 5.101.1 University of Malaya Pipeline Products & Ongoing Clinical Trials Overview
• 5.102 University of Maryland Company Overview
  • 5.102.1 University of Maryland Pipeline Products & Ongoing Clinical Trials Overview
• 5.103 University of Memphis Company Overview
  • 5.103.1 University of Memphis Pipeline Products & Ongoing Clinical Trials Overview
• 5.104 University of Pecs Company Overview
  • 5.104.1 University of Pecs Pipeline Products & Ongoing Clinical Trials Overview
• 5.105 University of South Florida Company Overview
  • 5.105.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview
• 5.106 Vanderbilt University Company Overview
  • 5.106.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
• 5.107 Vivex Biologics Inc Company Overview
  • 5.107.1 Vivex Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.108 Wayne State University Company Overview
  • 5.108.1 Wayne State University Pipeline Products & Ongoing Clinical Trials Overview
• 5.109 Wright Medical Group NV Company Overview
  • 5.109.1 Wright Medical Group NV Pipeline Products & Ongoing Clinical Trials Overview
• 5.110 Xtant Medical Holdings Inc Company Overview
  • 5.110.1 Xtant Medical Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview

6 Bone Grafts and Substitutes- Recent Developments

• 6.1 Oct 12, 2020: Fujifilm starts a clinical investigation in Europe on FF-37101, a bone grafting material useful for bone regeneration
• 6.2 Jul 07, 2020: New collagen supply agreement with NovaBone Products
• 6.3 Jun 29, 2020: DePuy Synthes renews cooperation agreement with AO Foundation to continue advancement of surgical education
• 6.4 May 28, 2020: Conformis announces settlement of patent dispute
• 6.5 May 19, 2020: Hackensack Meridian Health invests in EpiBone a regenerative medicine company
• 6.6 Apr 08, 2020: Wright Medical Group announces virtual meeting alternative to physical attendance at Extraordinary General Meeting of Shareholders and change of time and location of meeting
• 6.7 Apr 08, 2020: Anika takes actions to strengthen liquidity in light of covid-19
• 6.8 Mar 27, 2020: BBS-Bioactive Bone Substitutes has received a working capital loan to secure its financing
• 6.9 Mar 18, 2020: Collagen Solutions: Trading Update
• 6.10 Mar 11, 2020: Bone Therapeutics announces 2019 full year results
• 6.11 Mar 06, 2020: Pentax Medical donates USD430,000 worth of medical devices to fight novel corona virus (2019-ncov)
• 6.12 Mar 04, 2020: Biocomposites announces U.S. launch of new STIMULAN rapid cure 3cc product
• 6.13 Mar 02, 2020: Stryker announces new Investor Relations leader
• 6.14 Feb 28, 2020: Lattice Biologics reports Q1 2020 results
• 6.15 Feb 25, 2020: Bone Solutions successfully surpasses 1,000 implanted cases with OsteoCrete magnesium-based bone void filler
• 6.16 Feb 25, 2020: Antibe Therapeutics provides corporate update and reports Q3 2020 interim financial and operating results
• 6.17 Feb 25, 2020: Stryker announces nomination of new Director, Lisa Skeete Tatum
• 6.18 Feb 24, 2020: 2020 Catalyst award winner Medtronic hires Chief Inclusion and Diversity Officer
• 6.19 Feb 24, 2020: AbbVie announces extension of expiration date for exchange offers for Allergan notes
• 6.20 Feb 24, 2020: 2020 Catalyst Award Winner Medtronic hires Chief Inclusion and Diversity Officer
• 6.21 Feb 19, 2020: BBS-Bioactive Bone Substitutes: We are pleased to announce that the clinical result of ARTEBONE is positive yielding an outcome similar to patient's own bone graft
• 6.22 Feb 19, 2020: Integra LifeSciences reports fourth quarter and full-year 2019 financial results and provides 2020 financial guidance
• 6.23 Feb 18, 2020: Medtronic reports third quarter financial results 2020
• 6.24 Feb 14, 2020: CollPlant Biotechnologies raising $4.45 million in U.S. Private Placement
• 6.25 Feb 10, 2020: CollPlant announces appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors
• 6.26 Feb 07, 2020: Onkos Surgicals launches magnesium bone scaffolding technology
• 6.27 Feb 05, 2020: Stryker expands Flower Mound regional headquarters
• 6.28 Feb 04, 2020: Zimmer Biomet announces fourth quarter and full-year 2019 financial results
• 6.29 Jan 31, 2020: BONESUPPORT HOLDING signs an agreement on a working capital facility of SEK 60 million
• 6.30 Jan 30, 2020: Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion
• 6.31 Jan 28, 2020: aap Implantate AG: FY/19: Good fourth quarter with EUR 3.1 million revenue (+17%) results in 9% revenue growth in fiscal year 2019 - Milestones in key technologies silver coating and magnesium-based implants
• 6.32 Jan 28, 2020: Stryker reports 2019 results and 2020 outlook
• 6.33 Jan 23, 2020: Centinel Spine announces continued partnership with Performance Tech Motorsports
• 6.34 Jan 22, 2020: Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
• 6.35 Jan 16, 2020: Audax Private Debt provides financing to support Olympus Partners Investment in Soliant Health
• 6.36 Jan 15, 2020: MEDICREA reports 2019 annual sales
• 6.37 Jan 15, 2020: Orthocell receives A$2.9m R&D tax incentive refund
• 6.38 Jan 13, 2020: Antibe Therapeutics expands executive team in preparation for large market partnering
• 6.39 Jan 13, 2020: NuVasive announces preliminary unaudited fourth quarter and full year 2019 revenue results
• 6.40 Jan 13, 2020: ATEC announces preliminary 2019 revenue results and 2020 revenue outlook
• 6.41 Jan 12, 2020: Baxter announces preliminary net sales for the fourth-quarter and full-year 2019 and announces preliminary full-year 2020 guidance
• 6.42 Jan 09, 2020: Royal Biologics launches MAGNUS, a DMSO-free Viable Cellular Bone Allograft
• 6.43 Jan 09, 2020: Pomerantz law firm investigates claims on behalf of investors of Baxter
• 6.44 Jan 08, 2020: Zimmer Biomet appoints Keri P. Mattox as Senior Vice President of Investor Relations and Chief Communications Officer
• 6.45 Jan 08, 2020: Globus Medical reports preliminary record fourth quarter and full year sales results
• 6.46 Jan 07, 2020: SeaSpine announces preliminary results for fourth quarter and full-Year 2019; reports record revenue, driven by greater than 20% U.S. spinal implants growth
• 6.47 Jan 06, 2020: Exactech announces leadership transition
• 6.48 Jan 02, 2020: NuVasive appoints Matthew K. Harbaugh as chief financial officer
• 6.49 Dec 20, 2019: OrthoPediatrics Corp. announces U.S. launch of QuickPack
• 6.50 Dec 19, 2019: Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development
• 6.51 Dec 18, 2019: Biogennix reports record year for sales
• 6.52 Dec 13, 2019: Globus Medical announces Board of Director addition and departure
• 6.53 Dec 10, 2019: In2Bones: Introducing the new AlloAid BioNail implant
• 6.54 Dec 10, 2019: Anika commences full U.S. commercial launch of TACTOSET bone repair therapy at Orthopaedic Summit 2019: Evolving Techniques
• 6.55 Dec 09, 2019: BoneSupport CERTiFy study on Cerament Bone Void Filler now published in the journal of bone and joint surgery
• 6.56 Dec 09, 2019: Bone Bank Allografts announces partnership with Yankee Alliance
• 6.57 Dec 05, 2019: Orthofix names Kevin Kenny president of global spine business
• 6.58 Dec 05, 2019: Ted Bird and David Gill join Bio2 Technologies Board of Directors
• 6.59 Dec 04, 2019: Lumeon and Medtronic partner to deliver new models of care in Europe
• 6.60 Dec 03, 2019: Collagen Solutions: Interim Results for the six months ended 30 September 2019
• 6.61 Dec 03, 2019: RTI Surgical accelerates business transformation with senior leadership appointments
• 6.62 Dec 03, 2019: Heidi DeGrazia appointed Chief Financial Officer Of N2 Biomedical
• 6.63 Dec 03, 2019: Kuros announces final result of Capital Increase - total gross proceeds of CHF 12.5 million raised
• 6.64 Dec 02, 2019: Rosen, a highly ranked firm, announces filing of securities class action lawsuit against Baxter International

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer

List of Tables

List of Tables

• Table 1: Bone Grafts and Substitutes - Pipeline Products by Stage of Development
• Table 2: Bone Grafts and Substitutes - Pipeline Products by Segment
• Table 3: Bone Grafts and Substitutes - Pipeline Products by Territory
• Table 4: Bone Grafts and Substitutes - Pipeline Products by Regulatory Path
• Table 5: Bone Grafts and Substitutes - Pipeline Products by Estimated Approval Date
• Table 6: Bone Grafts and Substitutes - Ongoing Clinical Trials
• Table 7: Bone Grafts and Substitutes Companies - Pipeline Products by Stage of Development
• Table 8: Bone Grafts and Substitutes - Pipeline Products by Stage of Development
• Table 9: Adocia SAS Pipeline Products & Ongoing Clinical Trials Overview
• Table 10: BioChaperone BMP - Degenerative Disc Disease - Product Status
• Table 11: BioChaperone BMP - Degenerative Disc Disease - Product Description
• Table 12: Biochaperone BMP - Non-Union Fractures - Product Status
• Table 13: Biochaperone BMP - Non-Union Fractures - Product Description
• Table 14: BioChaperone BMP - Osteoporosis - Product Status
• Table 15: BioChaperone BMP - Osteoporosis - Product Description
• Table 16: Aesculap Biologics LLC Pipeline Products & Ongoing Clinical Trials Overview
• Table 17: NOVOCART DISC - Product Status
• Table 18: NOVOCART DISC - Product Description
• Table 19: Agenta Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• Table 20: B-247 Cranial Bone Graft Implant - Product Status
• Table 21: B-247 Cranial Bone Graft Implant - Product Description
• Table 22: Amend Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• Table 23: Biomimetic Bone - Product Status
• Table 24: Biomimetic Bone - Product Description
• Table 25: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• Table 26: Hyalobone - Product Status
• Table 27: Hyalobone - Product Description
• Table 28: Hyalofast - Product Status
• Table 29: Hyalofast - Product Description
• Table 30: Hyalograft C Autograft - Product Status
• Table 31: Hyalograft C Autograft - Product Description
• Table 32: Anika Therapeutics Inc - Ongoing Clinical Trials Overview
• Table 33: Hyalofast - A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast with BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control
• Table 34: Antibe Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• Table 35: CGX-227 - Product Status
• Table 36: CGX-227 - Product Description
• Table 37: CGX-443 - Product Status
• Table 38: CGX-443 - Product Description
• Table 39: Aperion Biologics Corp Pipeline Products & Ongoing Clinical Trials Overview
• Table 40: Z-Fix - Product Status
• Table 41: Z-Fix - Product Description
• Table 42: Z-Meniscus - Product Status
• Table 43: Z-Meniscus - Product Description
• Table 44: Z-Patch - Product Status
• Table 45: Z-Patch - Product Description
• Table 46: Arthro Kinetics AG Pipeline Products & Ongoing Clinical Trials Overview
• Table 47: CaReS plus - Product Status
• Table 48: CaReS plus - Product Description
• Table 49: Aursos, Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• Table 50: AUR-84 Resorbable Implant - Product Status

List of Figures

List of Figures

• Figure 1: Bone Grafts and Substitutes - Pipeline Products by Stage of Development
• Figure 2: Bone Grafts and Substitutes - Pipeline Products by Segment
• Figure 3: Bone Grafts and Substitutes - Pipeline Products by Territory
• Figure 4: Bone Grafts and Substitutes - Pipeline Products by Regulatory Path
• Figure 5: Bone Grafts and Substitutes - Pipeline Products by Estimated Approval Date
• Figure 6: Bone Grafts and Substitutes - Ongoing Clinical Trials